Based on the principle of "giving a voluntaru and informed consent on vaccination at their own costs and risks"
China has shortened the COVID-19 quarantine time for inbound international travelers and refined the designation of medium- and high-risk areas, in an effort to cope with the highly infectious Omicron variant more precisely, according to a document released on Tuesday.
China released its first diagnosis and treatment guideline for monkeypox on Wednesday, making it clear that the virus can spread through close contact and droplets, but most patients can recover without special treatment.
Medical device manufacturer SHINVA – which has operations in the Zhoucun district of Zibo city, located in East China's Shandong province – finished production of a group of mobile labs for nucleic acid sampling on May 17.
Scientists stressed the need to inoculate the vulnerable while urging vigilance against the newly discovered Omicron subvariants, and called for more research to understand their quick transmissibility and severity.
Some media outlets in the West are questioning China's dynamic COVID-19 clearance policy, saying the less severe Omicron variant doesn't necessitate such stringent measures. Is this the case? Should China change its course and let the virus have its way? Let's see.
Positive progress has been made in the development of monovalent and multivalent vaccines against the Omicron variants, a senior Chinese health official told a press conference on Saturday.
According to the Zibo emergency plan, if there are special needs for medical treatment in the quarantine area – such as for kidney dialysis, pregnant women in labor and tumor radiotherapy – the community and the person in need shall contact the designated medical institution in advance to make an appointment (24-hour contact number: 0533-6410321).
